Overview

Safety and Efficacy Study of Adult Human Mesenchymal Stem Cells to Treat Acute Graft Versus Host Disease (GVHD)

Status:
Completed
Trial end date:
2008-07-14
Target enrollment:
Participant gender:
Summary
To establish the safety and efficacy of two dose levels of Ex-vivo Cultured Adult HumanMesenchymal Stem Cells (Prochymal) in subjects experiencing acute GVHD, Grades II-IV, post hematopoietic stem cells (HSC) transplant.
Phase:
Phase 2
Details
Lead Sponsor:
Mesoblast, Inc.
Osiris Therapeutics
Treatments:
Methylprednisolone
Remestemcel-l